PRAC meeting highlights 13-16 May 2024
13/05/2024
Medicines for human use
Pharmacovigilance risk assessment committee (PRAC)
The European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) is responsible for assessing and monitoring safety issues for human medicines.
The current PRAC highlights from the May 2024 meeting provides further information on hydroxyprogesterone caproate medicines to be suspended from the EU market.